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Abstract
Vancomycin has a complex pharmacokinetic profile and 
carries potential risks for nephrotoxicity and ototoxicity. The 
pharmacokinetic profile in elderly patients significantly differs 
from that of younger patients. It is common practice in many 
institutions for pharmacists to intentionally round serum 
creatinine levels to 1 mg/dl in elderly patients with levels <1 mg/
dl to avoid overestimating clearance and toxicities. This can 
potentially lead to underestimation of creatinine clearance, and 
subsequently lead to vancomycin under dosing. The aim of this 
study was to evaluate vancomycin target trough attainment 
and the time to trough attainment with vancomycin dosing per 
pharmacy in elderly patients. 
Methods
In this retrospective study, patients 75 years and older who 
received vancomycin at our institution were evaluated. Subjects 
were included in the study if they were at least 75 years of 
age, received intravenous vancomycin therapy, and had 
a vancomycin trough drawn after the third dose. The study 
patients were divided into three serum creatinine groups; 
<0.8 mg/dl (LSCr), 0.8-0.9 mg/dl (MSCr), and ≥1 mg/dl (HSCr). 
Patients were excluded from the study if they did not meet 
inclusion criteria, had no trough levels drawn, or were <75 years 
of age. 
Results
Two hundred and four patients 75 years or older were included 
in the study. The target trough attainment was highest in the 
HSCr group (n = 37, 80%), which was significantly higher 
than the LSCr (n=21, 31%; p<0.0001) and MSCr (n=42, 46%; 
p<0.0001) groups. The time to target trough goals (days, mean 
± SD) differed between the three groups, with the LSCr group 
taking the longest duration: LSCr: 5.14 ± 2.5; MSCr: 3.74 ± 1.1; 
HSCr: 3.78 ± 1.6, p=0.005. 
Conclusion
Adjustments need to be done to improve vancomycin dosing 
per pharmacy in patients 75 years of age and older. This study 
shows that LSCr patients (<0.8 mg/dl) had the lowest rates of 
target trough level attainment. Intentionally rounding serum 
creatinine to 1 mg/dl if values are less when estimating renal 
function in this older patient population may not be predictive 
of true renal function and can decrease the likelihood of target 
attainment or increase time to target attainment.   
Lee H. Nguyen, PharmD, BCPS-AQ ID, APh; Martin Breen, PharmD; 
Jason Yamaki, PharmD, PhD; Geraldine Cadalin, BS; Nilomi Shah, BA;                    
Linda Lumintaintang, BS
Background
Vancomycin is a glycopeptide antibiotic used to treat drug-
resistant gram-positive bacteria, including methicillin-resistant 
Staphylococcus aureus.(1) It has been a widely used antibiotic 
since inception despite its complex pharmacokinetic profile and 
carries potential risks for nephrotoxicity and ototoxicity.(2-7) The 
vancomycin elimination rate constant and creatinine clearance 
have been suggested to be related to age. Additionally, there 
remains a sufficient amount of variability in clearance and 
volume of distribution observed in elderly patients.(8) Elderly 
patients may also have decreased muscle mass, which can lead 
to decreases in serum creatinine and affect drug distribution.(9) 
It has also been described that serum creatinine production in 
elderly patients may be within normal limits, but renal function 
may be lower than expected.(10) 
In many institutions, pharmacists perform vancomycin dosing, 
order serum concentrations for therapeutic drug monitoring, 
and adjust the vancomycin dose accordingly based on specific 
target trough goals, site of infection, and causative organism.(5)
Despite the clinical evidence that recommends against rounding 
serum creatinine when estimating clearance creatinine with 
the Cockcroft-Gault method, the practice remains.(9,11-17) Many 
institutions, including ours, have pharmacists who utilize serum 
creatinine rounding with the Cockcroft-Gault equation.(18-21) A 
common practice by the institutional pharmacists is to round up 
serum creatinine levels to 1 mg/dl if measured levels are <1 mg/
dl prior to use in creatinine clearance calculations in patients 65 
years of age or older. The rationale behind this is to account for 
lower muscle mass in the elderly, which can lead to lower serum 
creatinine levels and thus potentially an artificially high creatinine 
clearance, as previously described above. 
National guidance on appropriate dosing of vancomycin in 
elderly patients is lacking. The vancomycin guidelines endorsed 
by the American Society of Health-System Pharmacists (ASHP), 
the Infectious Diseases Society of America (IDSA), and the 
Society of Infectious Diseases Pharmacists (SIDP) do not 
provide best practices for dosing in older patients.(5) In addition, 
published reports pertaining to vancomycin dosing in elderly 
patients have been limited. However, a discussion of appropriate 
vancomycin dosing in elderly patients was recently started with 
Young and colleagues.(22)
Based on the data described above, limited national dosing 
guidelines, and the common practice of rounding serum 
creatinine to 1 mg/dl in elderly patients with serum creatinine 
levels of <1 mg/dl, more clinical data is needed to better 
understand the vancomycin utilization in the elderly population. 
The aim of this study was to evaluate vancomycin target trough 
attainment and the time to target trough attainment with 
vancomycin dosing per pharmacy in elderly patients, specifically 
in patients 75 years of age or older. We hypothesized that 
rounding of serum creatinine to 1 mg/dl in patients with serum 
creatinine levels of <1 mg/dl would lead to under dosing as 
evident by not achieving trough attainment or increasing time to 
trough target attainment. 
Methods
St. Joseph Health’s Institutional Review Board approved this 
study. In this retrospective study, patients 75 years and older 
who received vancomycin at our institution during the time 
period of January 1, 2014, to December 31, 2014, were evaluated 
for inclusion. All subjects were identified through MeditechTM 
Electronic Medical Record reports and pharmacy records. The 
study institution is a non-academic community hospital with 
325 beds. Subjects were included in the study if they were at 
least 75 years of age, received intravenous vancomycin therapy, 
and had a vancomycin trough drawn after the third dose. The 
study patients were divided into three groups: serum creatinine 
<0.8 mg/dl (LSCr), serum creatinine 0.8-0.9 mg/dl (MSCr), and 
serum creatinine ≥1 mg/dl (HSCr). The group designation was 
based on the value of serum creatinine when vancomycin was 
initiated. Only the first occurrence of vancomycin utilization 
was included in the study. Patients were excluded from the 
study if they did not meet inclusion criteria, had no trough levels 
drawn, or were less than 75 years of age. Vancomycin daily 
doses were based on the amount of vancomycin received in a 
24-hour period. Patient chart reviews were performed to extract 
pertinent demographics, laboratory, and clinical data, including 
gender, age, height, weight, infection, renal function tests, and 
vancomycin dosing and levels.
Statistical Analysis
Descriptive statistics were computed for all study variables that 
were measured on an interval or ratio scale. Discrete data were 
presented as frequencies and percentages. An independent 
student t-test was used to compare mean serum creatinine 
values and other continuous variables. The Pearson’s chi-square 
or Fisher’s test was used to measure the association between 
dichotomous variables. All tests were two-tailed and a P-value 
of <0.05 was considered significant. Statistical analyses were 
carried out with SPSS version 20.0 (Chicago, IL, USA) and 
GraphPad Prism version 6.0 (San Diego, CA, USA).
Results
Two hundred and four patients 75 years of age or older were 
identified as receiving vancomycin and a trough level after the 
third dose of vancomycin. The patient characteristics (mean ± 
SD) include age 85.7 ± 5.98 years, weight 68.6 ± 16.94 kg, and 
serum creatinine 1.25 ± 0.78 mg/dl, and consisted of mostly 
women, 65% (Table 1). The three serum creatinine groups were 
distributed as LSCr (n=67), MSCr (n=91), and HSCr (n=46). The 
demographic characteristics are shown in Table 1. The majority 
of the differences between the groups were due to the HSCr 
group being significantly different from the LSCr and MSCr 
groups. The LSCr group had more female subjects (75%) overall, 
and shorter (mean ± SD, 63.9 ± 3.7 inches) patients than the 
MSCr group (65.6 ± 3.8). The HSCr group had a lower total daily 
mg/kg dose of vancomycin (mean ± SD) than the other two 
groups (HSCR 15.2 ± 3.3 vs MSCr 18.4 ± 6.2, LSCr 18.5 ± 5.6), 
p=0.001. All three groups had more than half of the vancomycin 
trough goals set as 15-20 mg/dl and did not differ between the 
groups, p=0.148.
The overall vancomycin trough target attainment (Table 
1) was highest in the HSCr group (n=37, 80%), which was 
significantly higher than the LSCr (n=21, 31%; p<0.0001) and 
MSCr (n=42, 46%; p<0.0001) groups. The rates of the 10-15 mg/
dl vancomycin trough target attainment did not statistically differ 
between groups, LSCr, n=10 (15%); MSCr, n=23 (25%); HSCr, 
n=15 (33%), p=0.0813. The rates of target attainment for the 
15-20 mg/dl vancomycin troughs were higher in the HSCr group 
(n=22, 48%) compared to the other two groups, LSCr, n=11 
(16%); p<0.0001 and MSCr, n=19 (21%); p=0.0003. There were 
no significant differences in target trough attainment between 
low and high trough levels within each group (data not shown). 
The time to target trough goals (days, mean ± SD), differed 
between the three groups, LSCr: 5.14 ± 2.5; MSCr: 3.74 ± 1.1; 
HSCr: 3.78 ± 1.6, p=0.005. The LSCr group took significantly 
longer to reach target trough goals compared to the other two 
groups (LSCr vs MSCr, p=0.02 and LSCr vs HSCr, p=0.04).
Discussion
The current ASHP/IDSA/SIDP guidelines on vancomycin 
dosing do not address how vancomycin clearance should be 
calculated, or how to estimate creatinine clearance. Rather, 
the guidelines focus on what troughs or AUC/MIC to target for 
specific disease states and toxicity risks with vancomycin.5 This 
study evaluated a current practice of vancomycin dosing based 
on the knowledge that renal function declines in older patients. 
The groups included vancomycin per pharmacy in patients 75 
years of age or older and grouped by serum creatinine values 
(<0.8 mg/dl [LSCr], serum creatinine 0.8-0.9 mg/dl [MSCr], and 
serum creatinine ≥1 mg/dl [HSCr]). The study results show that 
the majority of patients were female and on average more than 
10 years older than the minimal inclusion age. The mean total 
body weights of each patient group did not differ, but the height 
of the LSCr group was statistically lower than that of the MSCr 
group. Patients with lower serum creatinine (<0.8 mg/dl) had the 
lowest rates of vancomycin trough attainment. When examining 
trough attainment with the higher trough goal of 15-20 mg/dl, we 
found patients with serum creatinine levels <1.0 mg/dl were less 
likely to achieve target attainment. In addition to the reduced 
rates of target attainment, the time to target trough was longer in 
patients with lower serum creatinine levels. The HSCr group had 
significantly higher levels of serum creatinine, suggesting true 
decreases in renal function, which likely attributed  to achieving 
the trough goals. 
Young and colleagues recently evaluated the impact of rounding 
serum creatinine levels to 1 mg/dl to dose vancomycin in 
patients ≥65 years of age. The study results suggest that actual 
serum creatinine levels may more accurately predict vancomycin 
troughs than rounded serum creatinine values.(22) The results 
of this study produced similar results to our own, suggesting 
older patients with rounded low serum creatinine values did not 
achieve vancomycin trough levels as readily as patients with 
higher serum creatinine levels, nor is the up-rounded serum 
creatinine value indicative of true renal function. Bourguignon 
and colleagues evaluated the pharmacokinetics of patients over 
the age of 80 years on vancomycin and found that there can be 
large inter-individual variability of vancomycin pharmacokinetic 
parameters.(8) Additional variabilities in protein binding and 
volume of distribution may also account for the differences in 
target trough attainment between groups.(23,24)  Moreover, the use 
of serum creatinine as an estimate of renal function in elderly pa- 
tients may not be reliable. Lower serum creatinine levels may 
be due to lower body mass, but as seen from our data, renal 
function may or may not be decreased. Renal function is thought 
to decline with age25, but the extent of renal function decline 
is difficult to ascertain. It has been described that one-third 
of elderly patients may not have a decline in renal function.26 
Because of the variability seen in elderly patients, alternative 
strategies need to be considered. 
Because of the limited body of clinical evidence, it would difficult 
to makes assumptions that vancomycin should be dosing by any 
specific method in elderly patients. The addition of this study 
reinforces the data presented by Young and colleagues that 
suggest vancomycin dosing in elderly patients is complex, and 
room for improvement is vast. Alternatively, instead of searching 
for correction factors or adjustments to dose vancomycin 
in elderly patients, adoption of new approaches should be 
considered. One potential approach to minimizing variability 
is to acquire two vancomycin levels to better determine the 
elimination rates. Hong and colleagues have used this technique 
to improve target trough attainment in the obese patient 
population.(27) Similar results of higher target trough steady-state 
achievement were seen in critically ill patients who had multiple 
vancomycin levels to predict renal function changes.(28)
Limitations
Our study has several limitations. The study is retrospective in 
design at a single institution, which limits the assessment to only 
the variables collected. This lack of randomization of the three 
groups may potentially cause a selection bias. The selection 
of serum creatinine cut-off values was arbitrary. Winter and 
colleagues similarly evaluated serum creatinine rounding with 
a threshold of 0.8 mg/dl and 1 mg/dl for rounding.(17) Evaluating 
the groups based on serum creatinine above and below 0.8 
mg/dl seemed reasonable. The rationale for the three groups 
was to have a single group act as a control group and the other 
groups with low-normal levels of creatinine as comparators. 
Clinical evidence is scarce when describing vancomycin dosing 
in elderly patients with low serum creatinine levels. Vancomycin 
dosing is based on variables such as gender, age, weight, and 
serum creatinine.(8,11,29,30) In our study, the patients in the LSCr 
and MSCr were similar in age, weight, and serum creatinine, 
thus allowing for comparisons with the HSCr group. Another 
limitation to the study is the potential for variations in clinical 
judgement by the clinical pharmacists despite the standardized 
protocol for dosing vancomycin. At our institution, only a handful 
of the same clinical pharmacists rotate to dose vancomycin as 
part of their clinical duties, which may limit some variation but 
not all. Lastly, the study did not control for critically ill patients 
or collect data on quantitative renal adjustment in various ages. 
Critically ill patients generally have different pharmacodynamics 
than stable patients.(28)
Conclusions
Adjustments need to be done to improve vancomycin per 
pharmacy in patients 75 years of age and older. This study 
shows that patients with low serum creatinine <0.8 mg/dl had 
the lowest rates of target trough level attainment, specifically for 
higher trough goals of 15-20 mg/dl. Use of serum creatinine to 
estimate renal function in older patients may not be predictive 
of true renal function. Further studies that investigate alternative 
dosing strategies with vancomycin need to be explored.
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Figure 1. Rate of Overall Target Trough Attainment by Serum 
Creatinine Group
Vancomycin trough target attainment was highest in the HSCr 
group (80%), which was significantly higher than both the LSCr 
(31%) and MSCr (46%) groups (p<0.0001).
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